Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study

This publication has 27 references indexed in Scilit:

• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
  Published by Elsevier ,2002
• Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials
  Arthritis & Rheumatism, 2000
• Musculoskeletal and systemic reactions to biological therapeutic agents
  Current Opinion in Rheumatology, 2000
• Long Term Safety of Infliximab
  Canadian Journal of Gastroenterology and Hepatology, 2000
• Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
  Gastroenterology, 1999
• Review article: safety of infliximab in clinical trials
  Alimentary Pharmacology & Therapeutics, 1999
• Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
  New England Journal of Medicine, 1999
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
  New England Journal of Medicine, 1997
• Autoantibodies to leucocyte antigens in hydralazine‐associated nephritis
  Journal of Internal Medicine, 1992
• D‐penicillamine‐induced lupus erythematosus
  Arthritis & Rheumatism, 1990